Noonan syndrome is caused by mutations in genes that control a critical cell-signaling pathway involved in growth and development. These mutations can be inherited from a parent or arise spontaneously, and they affect roughly 1 in 1,000 to 1 in 2,500 births. The result is a constellation of features that can include short stature, distinctive facial characteristics, heart defects, and bleeding problems.
The Core Genetic Cause
At the heart of Noonan syndrome is a group of gene mutations that all disrupt the same biological process: a signaling chain inside cells called the RAS-MAPK pathway. This pathway acts like a relay system, passing chemical signals from the surface of a cell to its nucleus, telling the cell when to grow, divide, or specialize. In Noonan syndrome, mutations cause this pathway to become overactive, essentially leaving the “grow” signal stuck in a partially-on position during fetal and childhood development.
Several different genes can carry the responsible mutation. The most commonly affected gene is PTPN11, which accounts for roughly half of all cases. Other genes involved include SOS1, RAF1, RIT1, KRAS, and LZTR1. Each of these genes encodes a different protein in the same signaling relay, which is why mutations in any one of them can produce overlapping symptoms. Because multiple genes feed into the same pathway, Noonan syndrome is sometimes grouped under a broader category called “RASopathies.”
The specific gene involved can influence which symptoms are most prominent. For example, mutations in the gene that regulates a protein called LZTR1 tend to be associated with heart muscle thickening, while other mutations correlate more strongly with valve defects or growth delays. This variation in symptoms from one patient to another has been one of the major challenges in developing targeted treatments.
How the Mutations Are Inherited
Noonan syndrome follows an autosomal dominant inheritance pattern, meaning a mutation in just one copy of the affected gene is enough to cause the condition. If a parent carries the mutation, each pregnancy has a 50% chance of passing it on.
In practice, the picture is more nuanced. Between 30% and 75% of families have an identifiable affected parent, which means a large share of cases arise from de novo mutations, or new genetic changes that occur spontaneously in the egg, sperm, or early embryo. A child with Noonan syndrome may be the first person in their family to carry the mutation. This is why many parents are surprised by the diagnosis, having no family history of the condition. When neither parent carries the mutation, the chance of a future sibling being affected is very low, limited essentially to the small possibility of the same spontaneous event happening again.
How It Affects the Heart
Heart defects are one of the most common consequences of Noonan syndrome, affecting the majority of people with the condition. The overactive growth-signaling pathway disrupts normal heart development in utero, and the type of defect varies.
Pulmonary valve stenosis, a narrowing of the valve that controls blood flow from the heart to the lungs, is the most frequent cardiac finding, present in roughly 25% to 71% of patients depending on the study. Holes between the heart’s upper chambers (atrial septal defects) occur in 4% to 57% of cases, while holes between the lower chambers (ventricular septal defects) appear in 1% to 14%. Thickening of the heart muscle, particularly in the left ventricle, is another hallmark and has been strongly linked to specific gene mutations like those in LZTR1 and RAF1. Less common findings include narrowing of the aorta (2% to 9%) and more complex structural defects.
The wide ranges in these numbers reflect differences in how studies define and detect each defect. Some are picked up on routine imaging in infancy, while milder forms may go unnoticed until later in life.
Effects on Growth and Stature
Short stature is a defining feature of Noonan syndrome, though children are often born at a normal length. Height typically begins to fall below the 3rd percentile after the first few years of life and stays there through puberty, which itself tends to be delayed. Average adult height for women with Noonan syndrome is around 152 to 154 cm (about 5 feet), and for men around 167 to 169 cm (roughly 5 feet 6 inches), placing both well below population averages.
About 40% of people with Noonan syndrome show low levels of growth hormone on testing, which contributes to the short stature. Growth hormone therapy is an approved treatment option and can improve final adult height, though the degree of benefit varies from person to person.
Bleeding and Bruising Risks
People with Noonan syndrome often bruise easily or bleed more than expected after injuries or surgeries. This happens because the same signaling pathway disruptions that affect heart and growth development also influence how the blood clotting system forms and functions.
The most common clotting abnormality is a deficiency in factor XI, one of the proteins that helps blood form a clot. In a systematic review of patients with confirmed bleeding disorders, factor XI deficiency was the single most frequent finding. Platelet-related problems, including low platelet counts and abnormal platelet function, were also common. About 21% of those with a diagnosed bleeding disorder had deficiencies in multiple clotting factors simultaneously, which can complicate surgical planning.
For many people, the bleeding tendency is mild and shows up mainly as easy bruising or prolonged bleeding from cuts. But it becomes clinically important before any surgery or dental procedure, which is why clotting function is typically assessed as part of routine management.
Why Symptoms Vary So Widely
One of the most confusing aspects of Noonan syndrome for families is how different it can look from one person to the next. Two siblings carrying the same mutation may have markedly different severity of symptoms. This happens for several reasons.
First, the specific location of the mutation within a gene matters. A mutation at one spot on the PTPN11 gene may produce mild facial features and no heart defect, while a mutation at a different spot on the same gene could cause significant pulmonary valve stenosis. Second, the rest of a person’s genetic background, the thousands of other gene variants they carry, can amplify or dampen the effects of the primary mutation. Third, the RAS-MAPK pathway is involved in so many different cell processes that even small differences in how strongly the pathway is activated can ripple out into very different physical outcomes across different organ systems.
This variability also means that some people with Noonan syndrome are diagnosed in infancy because of obvious heart defects or distinctive facial features, while others are not identified until childhood or even adulthood, when short stature or unexplained bleeding prompts genetic testing.